Search...
/
The Fly Cast
Press play to listen
Competitive Advantages
Risks
Tuesday
Aug 4, 8:12 AM
Over a week ago
Jul 31, 9:15 AM
Jul 31, 8:16 AM
Jul 31, 6:48 AM
Jul 30, 6:33 PM
Jul 30, 7:45 AM
Jun 24, 9:01 AM
May 20, 6:29 AM
May 19, 6:44 AM
May 18, 4:36 PM
May 4, 6:54 AM
Apr 30, 7:04 AM
Apr 29, 7:42 AM
Apr 29, 5:09 AM
Apr 28, 12:34 PM
Apr 28, 7:39 AM
Apr 21, 4:04 PM
Competitive Advantages
Proprietary Stereopure Chemistry Platform: Their PRISM platform enables the precise control of oligonucleotide stereochemistry, a foundational differentiator from conventional, mixed-stereoisomer approaches, allowing for rational design and optimization.
Potential for Superior Drug Profiles: The stereopure design is intended to yield oligonucleotides with improved potency, duration of effect, and safety profiles, potentially leading to better therapeutic outcomes.
Broad Modality and Disease Application: Their versatile platform allows for the development of multiple RNA modalities (e.g., antisense, splicing, siRNA) to address a wide range of genetic diseases across various therapeutic areas.
Risks
Clinical Trial Outcomes: Their product candidates may not achieve favorable results in clinical trials, leading to delays, failures, or discontinuation of development programs due to lack of efficacy or unacceptable safety profiles.
Regulatory Approval: Even if clinical trials are successful, their product candidates may not receive necessary regulatory approvals from health authorities like the FDA, hindering their ability to market and sell therapies.
Competition and Market Share: They face intense competition from larger pharmaceutical and biotechnology companies developing similar or alternative treatments, which could limit their market potential and profitability.
